Cognetivity Neurosciences' AI Powered CognICA Platform Wins Major Industry Award
Cognetivity Neurosciences' AI Powered CognICA Platform Wins Major Industry Award
CognICA Chosen as Winner of Best AI Product in Healthcare Award at CogX Festival
CognICA在CogX音樂節上被選為最佳人工智慧醫療產品獎獲得者
Vancouver, British Columbia--(Newsfile Corp. - September 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is delighted to announce that it has won a major AI technology award, with the company's CognICA platform being recognised in the CogX Awards as the Best AI Product in Healthcare for 2023. CognICA was chosen as the winner in a strong field of contenders and was recognised for both its technical excellence and potential for an enormous impact on the way healthcare is delivered globally. The award ceremony was conducted at the O2 Arena in London, UK and Cognetivity's co-founder and CIO Dr Seyed-Mahdi Khaligh-Razavi accepted the award on behalf of the company. The CogX awards are part of the CogX Festival, the world's biggest festival of inspiration, impact and transformational change, being held in London, UK from the 12th to 14th September, 2023. The event has an audience of over 90,000 people, features 500 speakers in 3 summits and over 1,000 startups.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年9月13日)-認知神經科學有限公司(CSE：CGN)(OTCQB：CGNSF)(FSE：1UB)(“公司”或“認知”)，領先的人工智慧(AI)醫療保健技術公司高興地宣佈，它獲得了一個重要的人工智慧技術獎，該公司的CognICA平臺被CogX Awards評為2023年最佳人工智慧醫療產品。CognICA被選為強有力的競爭者領域的獲勝者，並因其卓越的技術和對全球醫療保健提供方式產生巨大影響的潛力而受到認可。頒獎典禮在英國倫敦O2競技場舉行，Cognetivity的聯合創始人兼首席資訊官Seed-Mahdi Khaligh-Razavi博士代表公司領獎。CogX大獎是2023年9月12日至14日在英國倫敦舉行的CogX音樂節的一部分，CogX音樂節是世界上最大的靈感、影響和變革節日。該活動有超過9萬名觀眾，有3次峰會的500名演講者和1000多家初創公司。
CogX is a global leader in AI and emerging technology. Its mission is to bring clarity to, and accelerate adoption of AI across all organizations from global enterprises to startups, and help ensure a safe and responsible transition to an AI-driven society. Now in their seventh year, the CogX Awards have championed some of the finest practitioners of innovation across the world. The awards celebrate those innovators, visionaries, and change-makers who are impacting the world, helping us get the next ten years right. The Best AI Product categories recognize products and people who bring AI to life and by shaping our future will revolutionize our approach to real world problems.
CogX是人工智慧和新興技術領域的全球領先者。其使命是澄清並加快從全球企業到初創企業的所有組織對人工智慧的採用，並幫助確保全全和負責任地過渡到人工智慧驅動的社會。現在已經是第七個年頭了，CogX大獎已經表彰了世界各地一些最優秀的創新實踐者。這些獎項是為了表彰那些正在影響世界、幫助我們正確地度過下一個十年的創新者、遠見者和變革創造者。最佳人工智慧產品類別表彰將人工智慧帶入生活的產品和人，並通過塑造我們的未來將徹底改變我們處理現實世界問題的方法。
Cognetivity's co-founder and CIO Dr Seyed-Mahdi Khaligh-Razavi commented, "We are so pleased that the hard work of our team is being recognised and that our innovative and game-changing CognICA platform has attracted such a prestigious award. Our technology has the potential to truly transform the way that brain health is managed across the world and the time for this is now, as the early detection and management of brain health issues has never been more important." He added, "With new advances in treatments for Alzheimer's such as Eisai's leqembi and Eli Lilly's upcoming donanemab set to transform the treatment of Alzheimer's disease and finally bringing hope to millions of sufferers, and the need to finally properly look after our brains, the most important organ in our bodies, the time is now to make a difference."
Cognetivity的聯合創始人兼首席資訊官Seed-Mahdi Khaligh-Razavi博士表示：“我們很高興我們團隊的辛勤工作得到了認可，我們的創新和改變遊戲規則的CognICA平臺獲得瞭如此高的獎項。我們的技術有潛力真正改變世界各地管理大腦健康的方式，現在是時候了，因為早期發現和管理大腦健康問題從未像現在這樣重要。”他補充道：“隨著阿爾茨海默氏症治療的新進展，如衛材的leqembi和禮來公司即將推出的donanemab將改變阿爾茨海默病的治療方法，最終給數百萬患者帶來希望，以及最終需要妥善照顧我們的大腦--我們身體中最重要的器官--的需要，現在是時候做出改變了。”
Cognetivity Neurosciences' mission is to utilize its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of A Brighter Mind for a Fuller Life.
認知神經科學的使命是利用其人工智慧平臺技術來改變全球大腦健康的格局，提高向患者提供的護理質量，並減少提供者和付款人的負擔和成本，實現公司為富勒生活提供更光明心靈的願景。
-------
About Cognetivity Neurosciences
關於認知神經科學
Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Cognetivity's CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. CognICA is currently available for clinical use in the United States, United Kingdom, Europe, Canada and the Middle East, with regulatory approval in other regions expected later in 2023.
Cognetivity是一家技術公司，它開發了一種認知測試平臺，用於醫療、商業和消費環境。Cognetivity的CognICA使用人工智慧和機器學習技術來測試大腦大片區域的表現，以幫助檢測認知功能障礙的早期跡象。CognICA目前在美國、英國、歐洲、加拿大和中東可用於臨床，其他地區的監管部門預計將於2023年晚些時候批准。
On behalf of the Board of Directors
我謹代表董事會
"Sina Habibi"
Sina Habibi
《新浪哈比比》
新浪哈比比
Chief Executive Officer and Director
董事首席執行官兼首席執行官
Forward-looking statements:
前瞻性陳述：
Certain statements contained in this news release, including those identified by the words "anticipate," "assume," "believe," "plan," "estimate," "expect," "intend," "may," "should" and similar expressions, to the extent they relate to the Company or its management, constitute forward-looking information or statements (collectively, the "Forward-Looking Statements"). These forward-looking statements are not historical facts and reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions, and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on a number of assumptions regarding our current and future business strategies and the environment in which we operate. We assume no responsibility to update or revise forward-looking information to reflect new events or circumstances, except as required by law. Readers are cautioned not to place undue reliance on our forward-looking statements.
本新聞稿中包含的某些陳述，包括“預期”、“假設”、“相信”、“計劃”、“估計”、“預期”、“打算”、“可能”、“應該”以及類似的表述，在與公司或其管理層有關的範圍內，構成前瞻性資訊或陳述(統稱為“前瞻性陳述”)。這些前瞻性陳述不是歷史事實，反映了對未來結果或事件的當前預期。本新聞稿包含前瞻性陳述。這些前瞻性陳述不是對未來業績的保證，涉及難以預測的風險、不確定性和假設。此類陳述基於當前預期和各種估計、因素和假設，涉及已知和未知的風險、不確定性和其他因素。這些陳述和資訊是基於對我們當前和未來的業務戰略以及我們所處的經營環境的一些假設。除法律要求外，我們不承擔更新或修改前瞻性資訊以反映新事件或新情況的責任。告誡讀者不要過度依賴我們的前瞻性陳述。
The Canadian Securities Exchange is not responsible for the adequacy or accuracy of this release.
加拿大證券交易所不對本新聞稿的充分性或準確性負責。
For more information, please visit: website: or contact: info@cognetivity.com; media inquiries can be sent to pr@cognetivity.com.
如需更多資訊，請訪問：網站：或聯繫方式：info@cognetivity.com；媒體查詢可發送至pr@cognetivity.com。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。